Dividend investing is an important part of a long-term strategy for income investors. The SPDR Portfolio S&P 500 High Dividend ETF offers investors exposure to sectors ranging from real estate to financials.
Schwab U.S. Dividend Equity ETF's dividend growth has been rather disappointing lately. Recent reconstitutions have purged SCHD of outperformers and increased exposure to underperforming sectors. Is this just a temporary issue, or should you sell before fundamentals deteriorate even further?
SCHD is one of the most popular dividend funds in the world. It does not have a particularly high yield, but it does have many quality dividend growers in its portfolio. It also trades at relatively low multiples. The broader markets, on the other hand, are very pricey.
The Vanguard Dividend Appreciation ETF and the Schwab U.S. Dividend Equity ETF Income are among the top dividend ETFs to earn years of passive income. SCHD offers a much higher dividend yield but trails VIG in recent total returns.
I rate Schwab U.S. Dividend Equity ETF (SCHD) a buy and State Street® SPDR® S&P® Dividend ETF (SDY) a hold, favoring SCHD's quality-driven strategy. SCHD offers higher dividend yield (3.80%), lower P/E (13.50x), and lower fees (0.06%) than SDY's 2.58% yield, 17.27x P/E, and 0.35% expense ratio. SCHD's portfolio emphasizes quality screens and conviction, while SDY relies on backward-looking dividend track records, resulting in crowded trades and higher valuations.
Schwab U.S. Dividend Equity ETF (SCHD) offers a compelling alternative as the AI trade becomes crowded and valuations reflect high expectations. SCHD targets profitable, shareholder-friendly companies with strong balance sheets and reliable dividends, providing stability amid market uncertainty. In 2026, SCHD's 3.7% yield, sector diversification, and low technology exposure can balance portfolios dominated by volatile growth or AI names.
Schwab U.S. Dividend Equity ETF (SCHD) receives a lot of flack, with constant assertions of underperformance and better alternatives. SCHD underperforms broad indices recently, primarily due to AI-driven market moves and sector allocations. Current top holdings are heavily weighted in biotech/pharma, with sector concentration shifting annually via index reconstitution and rebalancing.
Launched on October 20, 2011, the Schwab U.S. Dividend Equity ETF (SCHD) is a passively managed exchange traded fund designed to provide a broad exposure to the Large Cap Value segment of the US equity market.
Schwab U.S. Dividend Equity ETF (SCHD) remains rated 'Sell' due to unattractive risk-reward versus Treasuries and sector headwinds. SCHD's 3.8% forward yield is less compelling with the Fed projecting only one 25-bps rate cut in 2026, keeping risk-free rates elevated. Overweight exposure to Energy sector is a concern given structural pressures and tepid 2026 outlook.
Schwab U.S. Dividend Equity ETF offers a compelling alternative to the S&P 500, emphasizing income, value, and broad sector diversification. SCHD delivers a 3.8% dividend yield, a 10.6% 10-year dividend CAGR, and a low 1-year beta of 0.44, supporting its 'sleep well at night' profile. Top holdings like MRK and CSCO provide undervalued dividend growth exposure, while the fund's sector mix reduces reliance on volatile mega-cap tech.
Investors love an ETF that offers a perfect balance between a good yield and some upside.
I am bullish on Schwab U.S. Dividend Equity ETF (SCHD) for its robust 9.15% dividend growth and compounding potential. SCHD's disciplined portfolio construction, sector caps, and focus on companies with 10+ years of dividend payments drive long-term income growth. Despite underperforming the S&P 500 and lower upfront yield than JEPI, SCHD's compounding delivers superior long-term income for patient investors.